As 23 pancreatic cancer patients were evaluated pre and post neoadjuvant therapy, the EphA2-EV levels in comparison to CA19-9 more accurately reflected the treatment status for patients with good or partial therapy responses. Here, EPHA2 is linked to pancreatic neoplasm.